Patients with PSMA expression in >50% of the tumor-associated vasculature were designated as the high PSMA expression group, while those with PSMA expression in ≤50% of the tumor-associated vasculature or no detectable PSMA expression were designated as the low PSMA expression group. This evidence concerns the gene FOLH1 and neoplasm.